Ellevest Inc’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Ellevest Inc’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2	Closed	–	–	1893
2022 Q2	$0	Buy	+2	New	+$53	﹤0.01%	1726

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ellevest Inc's ZNTL Position: Q3 2022 in Review

Ellevest Inc sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2022, closing a stake of 2 shares.

Ellevest Inc first reported a position in ZNTL in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 120 funds tracked by Wall St. Rank hold ZNTL as of Q3 2022.

Ellevest Inc reported no remaining Zentalis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Ellevest Inc sold 2 Zentalis Pharmaceuticals shares in Q3 2022.
Ellevest Inc first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Ellevest Inc's Zentalis Pharmaceuticals position peaked at $0 in Q2 2022.
120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2022.

Based on Ellevest Inc's 13F filing for Q3 2022, filed 2 Nov 2022.